Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Lymphoma|Hemophagocytic Lymphohistiocytoses
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+, The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival., The participant's survival would be assessed at 180 days from the malignancy diagnosis
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma